Participant profile: Myelo Therapeutics
Developing innovative treatments
that target areas of high unmet need
Myelo Therapeutics is a pharmaceutical company based in Germany that develops innovative treatments in areas of high unmet medical needs. The company’s lead compound, Myelo001, is an orally applied small molecule, currently being investigated in a phase IIa clinical trial.
Enter your email address to follow The Hive and get the latest updates on participants and milestones
Reducing the occurrence of chemotherapy-induced Neutropenia with Myelo001
Cytotoxic chemotherapy frequently suppresses the hematopoietic system, impairing host protective mechanisms. Chemotherapy-induced Neutropenia (CIN), the most serious hematologic toxicity, is associated with the risk of life-threatening infections.
As a consequence of such an infection it can become necessary to reduce dosage of or delay chemotherapy, which may compromise treatment outcomes. Myelo001 reduces the occurrence of CIN. In addition to its protective properties, Myelo001 is effective in preventing a broad range of viral infections, an important added benefit for immunosuppressed patients.
Myelo001 is the first new therapy option for chemotherapy-induced neutropenia (CIN) in over 20 years. Preclinical and first clinical studies confirmed good safety and efficacy in CIN prophylaxis. However, the molecular mode of action and binding site at the target molecule is not yet fully elucidated. This is the primary objective of Myelo Therapeutics’ non-clinical research program.
Broad expertise put to a great purpose
Myelo’s researchers have experience ranging from academia to Big Pharma R&D, covering areas such as neurology, ophthalmology, hematology, and immunology, and they now bring their knowledge and abilities to advance Myelo’s mission to tackle unmet needs.
Meet the team
Managing Director and Chief Medical Officer
After several years in big pharma R&D in Neurology, Ophthalmology and Hematology, Dirk co-founded start-up Myelo Therapeutics, where he leads the R&D team to develop novel molecules from preclinical to clinical phase 3 in areas of high unmet medical needs.
Participation in The Hive enables Myelo to conduct an optimized search of relevant data via software assisted literature research. This ability to view our research in context of the knowledge and expertise of the global scientific community will make our work more efficient.
Dr. Corinna Asang
Science and Clinical Trial Manager
After her PhD in HIV-1 RNA splicing followed by several years of postdoctoral research in the field of immunology and pediatric cancer at the University Hospital Düsseldorf, Corinna joined Myelo Therapeutics to develop the company’s antiviral research area.
Accessing the immune response’s molecular interactions and downstream pathways more rapidly, significantly optimizes. Together with additional data available from the research community, the Hive program speeds up the transition from experimental data to novel hypothesis for antiviral mechanisms.
Preclinical Research Manager
Patrik joined Myelo Therapeutics to direct the bulk of pre- and non-clinical research on Myelo001 afterstudying biochemistry at LMU in Munich and earning his master’s thesis on the stem cell-like seam cells in C. elegans at the Imperial College London.
Being part of the Hive provides us with easier access to relevant information via Elsevier’s software assisted literature research. Moreover, the ability to quickly connect the latest data with available literature knowledge helps us to streamline research analysis, which in turn speeds up our workflow, enabling better future research decisions and cost savings.
The Hive: Supporting Arctic Pharma in moving their R&D projects forward
Dirk Pleimes, Managing Director and Chief Medical Officer, is able to get an overview and optimized search of relevant data due to software assisted literature research. Screening a brought range of indication and putting findings from Myelo’s research in context of the vast knowledge available from the global scientific community is considerably facilitated with The Hive and renders his work more efficient.
Patrik Brehm, Preclinical Research Manager, also appreciates being able to get an easier overview due to software assisted literature research. Moreover, the possibilities of streamlining research analysis, by being able to quickly connect latest data with available literature knowledge, will speed up Patrik’s workflow, result in better future research decisions, and additionally save costs for Myelo Therapeutics. Furthermore, the exposure of Myelo Therapeutics through the Hive program will enable easier connections with potential research collaborators and allow Patrik to grow his network of scientific experts.
Dr. Corinna Asang, Science and Clinical Trial Manager, can quickly identify matching collaborators and establish creative partnerships keen on incubating scientific ideas. Accessing immune response’s molecular interactions and downstream pathways more rapidly optimizes her work significantly. Together with additional data available from the research community, this program speeds up the transition from experimental data to novel hypothesis for antiviral mechanisms.
Videos and media
Learn more about Elsevier's R&D solutions for drug discovery
and development utilized by Myelo Therapeutics:
Improve R&D productivity with a chemistry research solution that delivers experimental facts on chemical structures, properties, reactions and procedures.
Reaxys Medicinal Chemistry
Empower hit identification and lead optimization with normalized compound–target affinity data and comprehensive pharmacokinetic, efficacy, toxicity, safety and metabolic profiles.
Increase the discovery of biomedical evidence to support critical life sciences functions, with access to the world's most comprehensive biomedical literature database.
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Enable researchers to more effectively and efficiently search authoritative, full-text scientific, technical and health content through the use of smart, intuitive functionality.
Enable better understanding of biological processes underlying disease progression and treatment response, with a solution that helps researchers interpret experimental data from scientific literature.